CTMX
CytomX Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
CytomX Therapeutics has 5 disclosed suppliers and 5 disclosed customers in SEC filings.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Sentence• a one-time milestone payment of $5.0 million to ImmunoGen in prior year;
CTMX 10-Kaccession 0001193125-26-107146
SentenceIn August 2010, we entered into an agreement with UCSB, that grants us an exclusive license, with the right to sublicense, under the patent rights owned by UCSB covering mask and screening technologies relating to the identification and discovery of pro-protein biologics, including masks and substrates, for the identification of pro-proteins, for use in the fields of therapeutics, in vivo diagnostics, and prophylactics (the "UCSB Agreement").
CTMX 10-Kaccession 0001193125-26-107146
SentencePursuant to the BMS Agreement, the financial consideration from Bristol Myers Squibb was comprised of an upfront payment of $50.0 million and estimated research and development service fees, and we were initially entitled to receive contingent payments of up to $25.0 million for additional targets and contingent payments for development, regulatory and sales milestones.
SentenceUnder the terms of the Astellas Agreement, we received an upfront payment of $80.0 million, and Astellas was responsible for funding the cost of preclinical research and discovery activities of both parties for all Products and for funding the cost of development and commercialization of all Products worldwide.
CTMX 10-Kaccession 0001193125-26-107146
CytomX Therapeutics, Inc.
2.37
Linked news
Expected move
Inputsstraddle ±34.5%
spot 2.34exp Nov 20ATM strike 2ATM straddle 0.95IV 216%